To examine the safety and efficacy of response guided triple therapy (PEG-IFN, Ribavirin, Telaprevir) for the treatment of early chronic Hepatitis C Virus (HCV) infection.

Start Date01 Jan 2013

Sponsor / Collaborator

Kirby Institute

[+1]

NCT00976950

/ CompletedNot Applicable

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.

Start Date01 Sep 2009

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT00805857

/ WithdrawnNot Applicable

SCOLTA: SURVEILLANCE COHORT LONG-TERM TOXICITY ANTIRETROVIRALS

The SCOLTA project is a system for online surveying of adverse events to recently commercialized antiretroviral drugs and a sentinel for unexpected and late adverse events reactions arising during any antiretroviral treatment.Aim of the proposed study is:
to evaluate the prevalence and incidence of serious adverse events and serious unexpected adverse events in HIV-infected patients enrolled in the SCOLTA project Tipranavir cohort and to identify possible risk factors
the evaluation of tipranavir containing regimens durability, considering treatment interruption for each reason.

Start Date01 Jun 2008

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Tipranavir

100 Translational Medicine associated with Tipranavir

100 Patents (Medical) associated with Tipranavir

1,158

Literatures (Medical) associated with Tipranavir

01 Dec 2025·Nano-Micro Letters

Solution-Processed Thin Film Transparent Photovoltaics: Present Challenges and Future Development

Review

Author: Cho, Yuljae ; Hou, Bo ; Xing, Zhaohui ; Ma, Jie ; Stewart, Aisling ; Almutairi, Munerah M S ; Liu, Tianle ; Liu, Mengxia

Abstract:

Electrical energy is essential for modern society to sustain economic growths. The soaring demand for the electrical energy, together with an awareness of the environmental impact of fossil fuels, has been driving a shift towards the utilization of solar energy. However, traditional solar energy solutions often require extensive spaces for a panel installation, limiting their practicality in a dense urban environment. To overcome the spatial constraint, researchers have developed transparent photovoltaics (TPV), enabling windows and facades in vehicles and buildings to generate electric energy. Current TPV advancements are focused on improving both transparency and power output to rival commercially available silicon solar panels. In this review, we first briefly introduce wavelength- and non-wavelength-selective strategies to achieve transparency. Figures of merit and theoretical limits of TPVs are discussed to comprehensively understand the status of current TPV technology. Then we highlight recent progress in different types of TPVs, with a particular focus on solution-processed thin-film photovoltaics (PVs), including colloidal quantum dot PVs, metal halide perovskite PVs and organic PVs. The applications of TPVs are also reviewed, with emphasis on agrivoltaics, smart windows and facades. Finally, current challenges and future opportunities in TPV research are pointed out.

01 Apr 2025·MOLECULAR DIVERSITY

Functional characterization and structural prediction of hypothetical proteins in monkeypox virus and identification of potential inhibitors

Article

Author: Jarin, Tanima ; Islam, Muhammad Muinul ; Raen, Reana ; Islam, Redwanul ; Islam, Md Rabiul

The excessive activation of the monkeypox virus (MPXV-Congo_8-156) is linked to various skin and respiratory disorders such as rashes, fluid-filled blisters, swollen lymph nodes and encephalitis (inflammation of the brain), highlighting MPXV-Congo_8-156 as a promising target for drug intervention. Despite the effectiveness of Cidofovir, in inhibiting MPXV activity, its limited ability to penetrate the skin and its strong side effects restrict its application. To address this challenge, we screened 500 compounds capable of penetrating the skin and gastrointestinal tract to identify potent MPXV inhibitors. Various characterization schemes and structural models of MPXV-Congo_8-156 were explored with bioinformatics tools like PROTPARAM, SOPMA, SWISS-MODEL and PROCHECK. Using molecular docking in PyRx, we evaluated the binding affinities of these compounds with MPXV-Congo_8-156 and identified the top five candidates ranging from - 9.2 to - 8.8 kcal/mol. ADMET analysis indicated that all five compounds were safer alternatives, showing no AMES toxicity or carcinogenicity in toxicological assessments. Molecular dynamics (MD) simulations, conducted for 100 ns each, confirmed the docking interactions of the top five compounds alongside the control (Cidofovir), validating their potential as MPXV inhibitors. The compounds with PubChem CID numbers 4061636, 4422538, 3583576, 4856107 and 4800629 demonstrated strong support in terms of root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA) value, hydrogen bond analysis, and Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) analysis. Thus, our investigation identified these five compounds as promising inhibitors of MPXV, offering potential therapeutic avenues. However, further in vivo studies are necessary to validate our findings.

01 Mar 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Implementation of a novel method for the determination of plasma protein binding of highly bound compounds using the equilibrium dialysis method coupled with extraction to the organic phase and its comparison to known methods

Article

Author: Novak Ratajczak, Sanja ; Gabor-Worwa, Ewelina ; Gaud, Nilesh ; Gogola, Dawid ; Kuś, Kamil ; Kowal-Chwast, Anna ; Latacz, Gniewomir ; Brzózka, Krzysztof

Accurate determination of plasma protein binding (PPB) is crucial in understanding the pharmacokinetics and pharmacodynamics of drugs, particularly for highly bound compounds where traditional methods may fall short. In this study, we present a pioneering approach for the precise determination of PPB that takes advantage of the lipophilicity of highly bound compounds. Twenty four highly bound compounds (with a fraction unbound (f_u) from 10^-1 to 10^-6) were tested with the most commonly used method, i.e., the rapid equilibrium dialysis (RED) method, along with its modifications adapted especially for strongly bound compounds, including dilution, presaturation, competition, and flux-dialysis methods. The results of these methods were compared to data obtained with the modification of RED coupled with extraction to organic phase, and the correlations between them were presented. Comparison studies demonstrate the accuracy of our approach across a set of highly bound compounds within a twofold range. Moreover, PPB values were determined for venetoclax, amiodarone, montelukast, and fulvestrant, for which, to the best of our knowledge and after extensive review of the literature, it has not been possible with the standard RED method until now. In conclusion, our new method can be a big step forward in finding the PPB of strongly plasma protein-bound compounds. It gives us a better understanding of how drugs and proteins interact, which helps us make safer and more effective medicines.

News (Medical) associated with Tipranavir

22 Oct 2024

·www.biospace.com

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

- Key Insights from Viral Hepatitis, PBC, and MASH/Fibrosis Studies Highlight Gilead’s Ongoing Commitment to Advancing Life-Changing Liver Disease Research - FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting ® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif. More than 40 abstracts will be presented with key data, including 11 abstracts reporting new data on primary biliary cholangitis (PBC). The data will include findings from the RESPONSE trial that demonstrate the efficacy and safety pro Livdelzi ® (seladelpar) in people living with PBC and compensated cirrhosis. Additionally, data will be presented on the effects of Livdelzi on pruritus (chronic itching), a symptom that has significant impact on the quality of life of people living with PBC, along with interim long-term efficacy and safety results from the ongoing ASSURE study. Beyond PBC, Gilead will be presenting an interim analysis of the Phase 3 MYR301 study, which is evaluating people living with hepatitis Delta virus (HDV) who received bulevirtide monotherapy (2 mg for 144 weeks; 10 mg for 144 weeks; or 10 mg for 96 weeks) for chronic HDV and have been off treatment for 48 weeks. The study is evaluating whether or not patients treated with bulevirtide monotherapy for 2-3 years maintained virological and biochemical responses one year after stopping treatment. An additional 144-week analysis of patient-reported outcomes for individuals treated with bulevirtide 2 mg will also be presented, adding to the wealth of long-term data for the treatment for chronic HDV. “We’re excited to share our latest research at The Liver Meeting, as we push the boundaries of what’s possible in liver disease treatment. The breadth of this research reflects Gilead’s unwavering dedication to advancing life-changing science and shaping healthier futures for people living with liver disease,” said Anu Osinusi, Vice President of Clinical Development for Hepatitis, Respiratory and Emerging Viruses, Gilead Sciences. “The depth and range of our data, spanning both viral and inflammatory liver diseases, underscores our commitment to making a meaningful impact at every stage of a person’s journey in liver disease. Our goals go far beyond treatment alone—our work spans awareness, education, screening, diagnosis, and long-term care, all intending to address unmet needs and enhance treatment outcomes.” Gilead will also present hepatitis C virus (HCV) data which will include safety and tolerability outcomes for Epclusa ® (velpatasvir/sofosbuvir) in pregnant individuals with chronic HCV (the STORC study). As a special population that is often excluded from clinical research, these results may help clinicians better support pregnant people living with HCV, which in turn may reduce the risk of transmission to infants. Furthermore, real-world findings from the SVR10K study on HCV will be showcased, demonstrating the effects of direct-acting antivirals against all HCV genotypes across diverse regions. Late-breaking data from a Phase 2a open-label study assessing the safety and efficacy of novel combination therapies for chronic hepatitis B virus (HBV) will also be presented by Gilead. Key Abstracts at AASLD 2024: ID Abstract Title PBC 164 Efficacy and Safety of Seladelpar in Patients with PBC and Compensated Cirrhosis in the Phase 3 Placebo-controlled RESPONSE Trial 167 Attenuation, Near Resolution, and Prevention of Pruritis in Patients with PBC Treated with Seladelpar: A Secondary Analysis of Patterns of Pruritis Change in the RESPONSE Trial 4339 Alkaline Phosphatase Changes with Seladelpar Across Subgroups of Primary Biliary Cholangitis Patients in the RESPONSE Trial 4342 Seladelpar and Reductions in Lipids in Patients with Primary Biliary Cholangitis with and without Statin use in the Phase 3 Placebo-controlled RESPONSE Study 4341 Long-term Safety of Seladelpar 10 mg with up to 5 Years of Treatment in Patients with Primary Biliary Cholangitis Primary sclerosing cholangitis (PSC) 151 Associations Between Biomarkers and Magnetic Resonance Imaging-derived ANALI Score in Patients with Primary Sclerosing Cholangitis: Analysis from the Phase 3 PRIMIS Study HDV 1147 Efficacy and Safety of BLV Monotherapy for Chronic Hepatitis Delta: Post Treatment Results through 48 Weeks after the End of Treatment from an Interim Analysis of a Randomized Phase 3 Study MYR301 1193 Patient-reported Outcomes among Patients with Chronic Hepatitis Delta Treated with Bulevirtide 2 mg: A Long-term Analysis of the Phase 3 MYR301 Trial at 144 Weeks 139 Long-term Bulevirtide Monotherapy in Patients with HDV-related Compensated Cirrhosis: Effectiveness, Safety and Clinical Outcomes from the Retrospective Multicenter European Study (SAVE-D) HCV 222 Safety, Tolerability, and Outcomes of Velpatasvir/Sofosbuvir in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC) 1455 The SVR10K Study: A Real-world Data with Pangenotypic Direct-acting Antivirals across Multiple Diverse Regions 1476 Hepatitis C Treatment Uptake Differs by Gender among a Commercially Insured Population in the United States HBV 1380 Results from a Phase 2a, Open-label Study to Evaluate the Safety and Efficacy of Novel Combination Therapies Containing VIR-2218, Selgantolimod, and Nivolumab for the Treatment of Chronic Hepatitis B 1252 Effectiveness and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Suboptimal Response to Antiviral Therapy 1337 Characterization of Changes in Noninvasive Fibrosis Markers over 8 Years of Tenofovir-based Treatment in Chronic Hepatitis B Patients Enrolled in Two Phase 3 Trials Nonalcoholic steatohepatitis (NASH)/Fibrosis 1520 Prospective Validation of the Mediterranean Diet Adherence Screener (MEDAS) for Point-of-care Assessment of Diet Quality in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease For more information, including a complete list of abstract titles being presented at the meeting, please visit the AASLD website . In July 2023, the European Commission (EC) granted full Marketing Authorization (MA) for bulevirtide 2 mg for the treatment of adults with chronic HDV and compensated liver disease. Bulevirtide’s conditional MA license in Great Britain was converted to a full MA in August 2023 and a full MA was granted in Switzerland and Australia in 2024. In regions where it is not approved, including the U.S., bulevirtide 2 mg is an investigational product. In these regions, health authorities have not established the safety and efficacy of bulevirtide. Bulevirtide 10 mg is an investigational product and has not been approved anywhere. Cilofexor and selgantolimod are investigational compounds and are not approved by the FDA or any other regulatory authority; their safety and efficacy have not been established. Please see below for the U.S. Indications and Important Safety Information, including BOXED WARNINGS, for Epclusa and Livdelzi. U.S. Important Safety Information And Indication for EPCLUSA BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated. Contraindications If EPCLUSA is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information. Warnings and Precautions Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir containing regimen. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia. Risk of Reduced Therapeutic Effect Due to Use with P-gp Inducers and/or Moderate to Strong Inducers of CYP2B6, CYP2C8 or CYP3A4 : Rifampin, St. John’s wort and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations. Adverse Reactions The most common adverse reactions (≥10%, all grades) with EPCLUSA in adults and pediatric patients 6 years of age and older were headache and fatigue; and when used with RBV in adults with decompensated cirrhosis were fatigue, anemia, nausea, headache, insomnia and diarrhea. The most common adverse reactions (≥10%, grade 1 or 2) in pediatric patients less than 6 years of age were vomiting and spitting up the drug. Drug Interactions Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan. Coadministration of EPCLUSA is not recommended with proton-pump inhibitors, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir. Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments. Indication EPCLUSA is indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis. U.S. Important Safety Information for LIVDELZI Warnings and Precautions Fractures: Fractures occurred in 4% of LIVDELZI-treated patients compared to no placebo-treated patients. Consider the risk of fracture in the care of patients treated with LIVDELZI and monitor bone health according to current standards of care. Liver Test Abnormalities: LIVDELZI has been associated with dose-related increases in serum transaminase (AST and ALT) levels > 3 x ULN in patients receiving 50 mg and 200 mg once daily (5x and 20x higher than the recommended dosage of 10 mg once daily). Perform baseline clinical and laboratory testing when starting LIVDELZI and monitor thereafter according to routine patient management. Interrupt treatment if the liver tests (ALT, AST, total bilirubin, and/or ALP) worsen, or if the patient develops signs and symptoms of clinical hepatitis (eg, jaundice, right upper quadrant pain, eosinophilia). Consider permanent discontinuation if liver tests worsen after restarting LIVDELZI. Biliary Obstruction: Avoid use of LIVDELZI in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt LIVDELZI and treat as clinically indicated. Adverse Reactions The most common adverse reactions (≥5%) with LIVDELZI were headache (8%), abdominal pain (7%), nausea (6%), abdominal distension (6%), and dizziness (5%). Drug Interactions OAT3 Inhibitors and Strong CYP2C9 Inhibitors: Avoid coadministration with LIVDELZI due to increased LIVDELZI exposure. Rifampin: Monitor biochemical response (e.g., ALP and bilirubin) when patients initiate rifampin during LIVDELZI treatment. Coadministration may result in delayed or suboptimal biochemical response of LIVDELZI. Dual Moderate CYP2C9 and Moderate-to-Strong CYP3A4 Inhibitors and BCRP Inhibitors (eg, cyclosporine): Monitor closely for adverse effects. Concomitant administration with LIVDELZI may increase LIVDELZI exposure. CYP2C9 Poor Metabolizers Using Moderate-to-Strong CYP3A4 Inhibitors: Monitor more frequently for adverse reactions as concomitant use of a moderate-to-strong CYP3A4 inhibitor in patients who are CYP2C9 poor metabolizers may increase LIVDELZI exposure and risk of LIVDELZI adverse reactions. Bile Acid Sequestrants: Administer LIVDELZI at least 4 hours before or 4 hours after taking a bile acid sequestrant, or at as great an interval as possible. Pregnancy and Lactation Pregnancy: There are insufficient data from human pregnancies exposed to LIVDELZI to allow an assessment of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Report pregnancies to Gilead Sciences, Inc., at 1-800-445-3235. Lactation: There are no data on the presence of LIVDELZI in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LIVDELZI and any potential adverse effects on the breastfed infant from LIVDELZI. Indication LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction of ALP. Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Limitations of Use: Use of Livdelzi is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy). About HDV HDV is considered the most aggressive or severe form of viral hepatitis, associated with more rapid progression towards liver-related death and liver cancer in people with HBV. On average, HDV progresses to cirrhosis within 5 years and to liver cancer within 10 years. Nearly 5% of people who have a chronic infection with HBV are estimated to have HDV, equating to 12-15 million people worldwide. The prevalence of HDV infection is largely underestimated due to lack of universal testing of HBV-positive individuals for HDV. About PBC PBC is a rare, chronic inflammatory liver disease primarily affecting women (1 in 1,000 women over the age of 40 or about 130,000 total people in the U.S.). PBC is characterized by impaired bile flow (known as cholestasis) and the accumulation of toxic bile acids in the liver, leading to inflammation and destruction of the bile ducts within the liver and causing increased levels of alkaline phosphatase (ALP), alanine transaminase (ALT) and gamma-glutamyl transferase (GGT), enzymes found primarily in the liver, as well as total bilirubin. The most common symptoms of PBC are pruritus and fatigue, which can be debilitating for some people. Progression of PBC is associated with an increased risk of liver-related mortality. About Gilead Sciences in Liver Disease For decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. We have helped to transform hepatitis C from a chronic condition into one that can be cured for millions of people. For people living with hepatitis B or D, our focus on advancing our medicines drives hope that today’s research will turn into tomorrow’s cures. Beyond viral hepatitis, we’re working to deliver advanced treatments for people living with PBC. But our commitment doesn’t stop there. Through our ground-breaking science and collaborative partnerships, we strive to create healthier futures for everyone living with liver disease. We are committed to a future without liver disease. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials or studies, including those involving Epclusa, Hepcludex (bulevirtide), Livdelzi (seladelpar), cilofexor and selgantolimod (such as the ASSURE, RESPONSE, MYR301, STORC and SVR10K studies); uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that the FDA and other regulatory authorities may not approve bulevirtide for the treatment of HDV, and the risk that any such approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of investigational programs for indications that are currently under evaluation and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. Epclusa, Hepcludex, Livdelzi, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company’s website at , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Contacts Meaghan Smith, Media public_affairs@gilead.com Jacquie Ross, Investors investor_relations@gilead.com

Phase 2Clinical ResultDrug ApprovalPhase 3

15 Mar 2024

·www.medicalplasticsnews.com

TekniPlex Healthcare debut solutions at Interphex NYC

TekniPlex Healthcare will emphasise its expertise and intellectual property related to the single-use bioprocessing and the cell and gene therapy markets at Interphex NYC, 16-18th April. At its Booth 3837, the company will highlight its portfolio for the burgeoning biologics niche, for which it supplies solutions across the upstream, downstream processing and final fill operations. Solutions include customisable barrier cleanroom films, tubing such as weldable TPE and TPV, silicone and PVC, as well as various compounds for associated moulded components. For cell and gene therapy applications, TekniPlex Healthcare is a company in the production and supply of tubing in a variety of configurations, grades and durometers. Both single- and multi-lumen constructions are available, as are multi-layer versions incorporating complementary materials for performance optimisation. For traditional bioprocess applications, TekniPlex Healthcare produces tight-tolerance biopharm-grade constructions comprised of TPE, TPV and silicones. For each of its offerings, the company’s manufacturing prowess boasts extrusion across four continents, and covers all stages of the drug development process, from small batch production through scale-up and commercial quantities. Also at INTERPHEX NYC, TekniPlex Healthcare will show its coextrusion film capabilities, including newly expanded cleanroom manufacturing capacity for multilayer films suitable for single-use bioprocessing applications. Situated in the company’s Puurs, Belgium facility, the new ISO 7 cleanroom multilayer blown film line joins existing cast coextrusion ISO 7 cleanroom manufacturing capacity suitable for bioprocessing bag film production. The additional film production further expands the company’s capabilities to provide customisable film solutions to bioprocessing bag manufacturers, with a wide range of potential resin combinations helping meet durability needs, as well as extractables and leachables profile requirements. The company’s assets also include a pilot film coextrusion line in its Global Innovation Center in Holland, OH for quick prototyping, helping biopharma-focused companies iterate film options quickly to reduce go to market time and costs. The company also has recently installed cleanroom bag prototyping equipment allowing it to assemble 2-D single-use bioprocessing bags for concept validation and application testing purposes. “As the biologics sector continues its steady growth, so does the need for high-quality materials and components suppliers who can also be innovative solutions partners,’ said Chris Qualters, CEO of TekniPlex Healthcare. “With our expanding capacities and innovative mindset, TekniPlex Healthcare is poised and ready to respond to the evolving needs of the sector, providing value-added solutions that help bring life-changing therapies to market.”

21 Dec 2023

·synapse.patsnap.com

Understanding Proteases Inhibitors and Methods to Keep Abreast of Their Recent Developments

Proteases are enzymes that play a crucial role in the human body by breaking down proteins into smaller peptides or amino acids. These enzymes are involved in various physiological processes, including digestion, blood clotting, immune response, and cell signaling. Proteases help in the breakdown of dietary proteins into absorbable nutrients, aiding in digestion and nutrient absorption. They also regulate blood clotting by activating clotting factors. Additionally, proteases are involved in immune response by degrading foreign proteins and pathogens. Furthermore, these enzymes participate in cell signaling pathways, influencing various cellular processes such as growth, differentiation, and apoptosis. Overall, proteases are essential for maintaining proper protein homeostasis and ensuring the normal functioning of the human body. Viral proteases are a class of enzymes that hydrolyze the peptide chain structure of proteins and are essential enzymes for viral biosynthesis. Their function is to cleave and modify precursor proteins to obtain mature active proteins, thereby exerting normal physiological functions. Proteases play a crucial role in the life cycle of viruses, and proteases of different viruses have a certain degree of similarity. Therefore, viral proteases have become ideal targets in the development of broad-spectrum antiviral drugs. Most of the antiviral drugs approved by the Food and Drug Administration (FDA) are peptide analogs and macrocyclic compounds. They bind to the active site of the target protease, thereby exerting antiviral effects. Protease inhibitors against AIDS and Hepatitis C virus are the most innovative sources in the development of antiviral drugs, with at least half of antiviral drugs used to treat AIDS. FDA-approved protease inhibitors for AIDS include saquinavir, indinavir, ritonavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir, and combination preparations. The analysis of the target Protease in the pharmaceutical industry reveals a competitive landscape with companies at different stages of development. Shanghai Pharmaceutical (Group) Co., Ltd. is leading with an approved drug, while other companies are in Phase 1 or Preclinical stages. The approved indications cover a wide range of medical conditions, indicating the potential therapeutic applications of drugs targeting Protease. The drug types progressing rapidly include Enzyme, Small molecule drug, and Chemical drugs, with biosimilars contributing to intense competition. China, the United States, and European countries are actively developing drugs targeting Protease. The future development of the target Protease will depend on the success of ongoing research and development efforts, as well as the ability of companies to bring innovative drugs to market. How do they work?Protease inhibitors are a class of drugs that inhibit the activity of proteases, which are enzymes responsible for breaking down proteins. Proteases play a crucial role in various biological processes, including digestion, blood clotting, and immune response. By inhibiting proteases, protease inhibitors can interfere with these processes and have therapeutic effects. From a biomedical perspective, protease inhibitors are commonly used in the treatment of viral infections such as HIV/AIDS. HIV protease inhibitors specifically target the protease enzyme of the human immunodeficiency virus (HIV), preventing it from cleaving viral polyproteins into functional proteins. This inhibition disrupts the viral replication cycle and helps control the progression of HIV infection. Protease inhibitors can also be used in the treatment of other medical conditions, including hepatitis C, cancer, and certain autoimmune disorders. In cancer therapy, protease inhibitors can help prevent the growth and spread of tumors by blocking proteases involved in tumor invasion and angiogenesis. It is important to note that protease inhibitors can have side effects and may interact with other medications. Therefore, their use should be carefully monitored and prescribed by healthcare professionals. List of Protease InhibitorsThe currently marketed Protease inhibitors include: Chymotrypsin(Shanghai Pharmaceuticals Holding Co., Ltd.)ANG-003Bismuthyl EcabetChymotrypsinogen/trypsinogenCGT-1507EP-007FLT3 TriTACIgA proteases(IGAN Biosciences)MRX-18Aprotinin(Bayer Ag)For more information, please click on the image below. What are Protease inhibitors used for?Protease inhibitors are commonly used in the treatment of viral infections such as HIV/AIDS. For more information, please click on the image below to log in and search. How to obtain the latest development progress of Protease inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of Protease inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Tipranavir

External Link

KEGG	Wiki	ATC	Drug Bank
D08605	Tipranavir	J05AE09	DB00932

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	22 Jun 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B	Phase 3	United States	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis B	Phase 3	Argentina	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis B	Phase 3	Brazil	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis B	Phase 3	France	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis B	Phase 3	Germany	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis B	Phase 3	Italy	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis B	Phase 3	Spain	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis C	Phase 3	United States	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis C	Phase 3	Argentina	Boehringer Ingelheim GmbH	01 Mar 2007
Hepatitis C	Phase 3	Brazil	Boehringer Ingelheim GmbH	01 Mar 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2020	Not Applicable	Acquired Immunodeficiency Syndrome	-	TPV in lipid-based formulation	zqbkvnrtqp(xhdtrdvxjc) = ckokkuctva cmqjalznjh (aosqdiluct )	-	01 Jan 2020
				TPV in lipid-free formulation	zqbkvnrtqp(xhdtrdvxjc) = curjkysvht cmqjalznjh (aosqdiluct, 4.7)
NCT00486330 (BUTI, CTgov)	Not Applicable	HIV Infections	12	Ritonavir+Tipranavir	sunbfcavhz(qqbezmmjvo) = igzvkpqxol fbdxsoldqy (kipuasbalb, qjklborcia - byqjfqlzff) View more	-	21 Nov 2012
NCT00076999 (1182.14/PACTG1051, CTgov)	Phase 1	HIV Infections	115	Tipranavir (TPV OS 2-<6 Yrs)	sqsreksuub = gzbsbzinxb amxbkflgjr (fqsijbhome, mutzqkdhwn - rnxmoddwnf) View more	-	25 Jul 2011
				Tipranavir (TPV OS 6-<12 Yrs)	sqsreksuub = gumqehkgdp amxbkflgjr (fqsijbhome, utdfllxtgk - itofguuzbk) View more
NCT00144170 (RESIST 2, CTgov)	Phase 3	HIV Infections	882	Tipranavir (with low dose ritonavir) (Tipranavir(TPV)/Low Dose Ritonavir(r))	csrovcsdiw = qlmysyaxmy ocyckjxehx (nxvnkfpwan, vkwdshebpz - jrqzoakspa) View more	-	23 Dec 2009
				Comparator protease inhibitor(CPI)/low dose ritonavir(r) (Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r))	csrovcsdiw = yqsccyazle ocyckjxehx (nxvnkfpwan, uakaiitknl - yzlryfbnjj) View more
NCT00144170 (RESIST 2, Pubmed \| BMC Infect Dis)	Phase 2/3	HIV Infections	882	Ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID	yanoriunwk(xeuvfmgomz) = eckbhsnmlh hmmhfhimpv (igbrvurlql ) View more	-	14 Dec 2009
NCT00440271 (CTgov)	Phase 3	HIV Infections	33	Optimized Background Regimen (OBR)+ritonavir+tipranavir (Standard of Care (SoC))	ydvvtzthmc(dtriysrptw) = xjkxpvytju jbfladqenl (rcqejfudzu, gjvfomydlp - narbpdnkvw) View more	-	26 Nov 2009
				Optimized Background Regimen (OBR)+ritonavir+tipranavir (Therapeutic Drug Monitoring (TDM))	ydvvtzthmc(dtriysrptw) = uuwjusteiv jbfladqenl (rcqejfudzu, gbyianjfaq - uhdtbsmfah) View more
NCT00054717 (CTgov)	Phase 3	HIV Infections	630	Ritonavir(r)+Tipranavir	fbhyxyzufo = zswgajrlbz ivdvjygics (ihfiaigjju, ffgaaqrqcc - uivdyrlloi) View more	-	19 Nov 2009
IAS2009	Not Applicable	-	75	Tipranavir (TPV)	kqvnisdgrb(vjwptamuxb) = rkqpzzxahg jlwojnidkp (bmjexlhuuq )	-	01 Jan 2009
				Darunavir (DRV)	oqufzasqop(qlzteuezca) = mhyznqtayr nlzzthasqx (wztzaxaoot )
NCT00076999 (1182.14/PACTG1051, Pubmed \| AIDS)	Phase 1	HIV Infections	115	TPV/r 290/115 mg/m	jqiarbeosx(iszofllamb) = 6.3% of patients lsnwvvyeda (alcpwmkpku ) View more	-	12 Sep 2008
				TPV/r 375/150 mg/m
IAS2008	Not Applicable	-	78	APTIVUS oral solution	byrxcctwrv(idnyvffltf) = unriqlfzno zajujotaga (tdgdcuywzg ) View more	-	01 Jan 2008
				APTIVUS capsules	byrxcctwrv(idnyvffltf) = sbtfuomcdw zajujotaga (tdgdcuywzg ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis